Home › Multiple Myeloma › North Carolina › Durham
Multiple Myeloma clinical trials in Durham, NC
37 studies for Multiple Myeloma are looking for participants at sites in and around Durham (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RecruitingPhase 3
- Research Site, Chapel Hill · 10 mi away
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
RecruitingPhase 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 mi away
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RecruitingPhase 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
RecruitingPhase 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 mi away
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecruitingPhase 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RecruitingPhase 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 2
- University of North Carolina Medical Center, Chapel Hill · 10 mi away
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RecruitingPhase 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10 mi away
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
RecruitingPhase 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mi away
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RecruitingPhase 1/2
- GSK Investigational Site, Chapel Hill · 10 mi away
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RecruitingPhase 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RecruitingPhase 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RecruitingPhase 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 mi away
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Recruiting
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi away
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
RecruitingPhase 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RecruitingPhase 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 mi away
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
RecruitingPhase 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 mi away
Selinexor and Backbone Treatments of Multiple Myeloma Patients
RecruitingPhase 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 mi away
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
RecruitingPhase 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi away
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
RecruitingPhase 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mi away
Registry of Older Patients With Cancer
RecruitingObservational study
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi away
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RecruitingPhase 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
RecruitingPhase 2
- University of North Carolina, Chapel Hill · 10 mi away
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RecruitingPhase 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
RecruitingPhase 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 mi away
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
RecruitingPhase 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 mi away
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RecruitingPhase 1
- University of North Carolina, Chapel Hill · 10 mi away
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RecruitingPhase 1
- University of North Carolina, Chapel Hill · 10 mi away
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RecruitingPhase 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mi away
Registry for Adults With Plasma Cell Disorders (PCD's)
RecruitingObservational study
- North Carolina Cancer Hospital, Chapel Hill · 10 mi away
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi away
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RecruitingPhase 1
- Duke University Health System (DUHS), Durham
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA41 studies
- Houston, TX38 studies
- Nashville, TN32 studies
- Denver, CO27 studies
- Rochester, MN24 studies
- St. Louis, MO24 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- Chicago, IL22 studies
- Seattle, WA22 studies
Other studies in Durham
- Breast Cancer63 studies
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer39 studies
- Metastatic Cancer33 studies
- Acute Myeloid Leukemia33 studies
- Lung Cancer32 studies
- Prostate Cancer32 studies
- Colorectal Cancer28 studies
- Chronic Lymphocytic Leukemia27 studies
- Ovarian Cancer27 studies
- Heart Failure26 studies
- Pancreatic Cancer24 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.